Neuron23, Inc.
Biotechnology
Neuron23 is a clinical-stage biotechnology company specializing in precision medicines for genetically defined neurological and immunological diseases. Leveraging advanced AI-based drug discovery models, Neuron23 aims to identify novel molecular targets and develop efficient, personalized treatments to improve patient outcomes.
Nancy Stagliano CEO, Board Chair |
Sam Jackson Chief Medical Officer |
Steve Wood SVP Drug Discovery |
Arash Rassoulpour SVP Research Operations |
Zhonghua Pei SVP Chemistry and DMPK |